| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 interim results example | Phase 1 | — | Subscribe to access the data. | Biologics | Renal/Genitourinary System | ||
Phase 1 interim results example | Phase 1 | — | Subscribe to access the data. | Biologics | Renal/Genitourinary System | ||
Phase 1 interim results example | Phase 1 | — | Subscribe to access the data. | Biologics | Renal/Genitourinary System |
Recent Updates
Recently added Catalysts
Jade Biosciences, Inc.$20.95
-1.53 (-6.81%)
C 42Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.10 B
EPS
-2.99
P/E Ratio
-
Value Trade
9.70 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
36.05 M
Operating CF
-24.08 M
Total Assets
319.43 M
Total Liabilities
22.97 M
Equity
296.46 M
D/E Ratio
12,345
-5 %
Week
-3.48 %
1 Month
52.44 %
3 Month
94.31 %
6 Month
-97.73 %
5 Year
-97.73 %
All Time
Cash Data
Cash Position
311.29 M
Monthly Burn
8.03 M
Runway
36.6 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.41 M
52 Week Range
6.57 - 28
% held by Insiders
17.71 %
% held by Institutions
68.05 %
Enterprise Value
785.67 M
Total Shares
49.30 M
Short %
19.7 %
Float Shares
41.37 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jade Biosciences, Inc.
155Total events
9Upcoming
25Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 9
Event history 146
Jun 25, 2026
Jun 5, 2026
▼Equity OfferingCorporate
Closed public offering of 11,500,000 shares at $15.00 per share, gross proceeds $172.5 million
Jun 5, 2026
◆Oral PresentationJADE101Presentation
Oral presentation at ERA 2026: Interim Phase 1 results
IgA nephropathysource ↗
Jun 4, 2026
◆Oral PresentationJADE101Presentation
Oral presentation at ERA 2026: Phase 2 JUNIPER trial design
IgA nephropathysource ↗
Jun 3, 2026
◆Equity OfferingCorporate
Jade Biosciences announces proposed underwritten public offering of common stock and pre-funded warrants
Jun 1, 2026
◆Oral PresentationJADE101Presentation
Conference call to discuss interim Phase 1 healthy volunteer results for JADE101
IgA nephropathysource ↗
Jun 1, 2026
Jun 1, 2026
Jun 1, 2026
Jun 2026
▲First Patient DosedJADE-001Trial
First-in-human healthy volunteer data expected
IgA nephropathysource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $226M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 61%
Micro Cap (rank 357 of 912)
Percentile RankJade Biosciences, Inc. carries a moderate pipeline score (42/100), with $565M risk-adjusted pipeline value, led by JADE101 in IgA Nephropathy (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JADE101 Small molecule | IgA Nephropathy | Phase 2 | NCT07541287 | 16% | $530M | RECRUITING | 30 | VERY_FAST | F (17) | Apr 1, 2029 | - | LOW Jul 7, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
JADE101 | IgA nephropathy | Phase 1 | 2026-06-01 | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101; >70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeks Read More | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy Read More | |
JADE101 | IgA nephropathy | Phase 1 | 2026-06-01 | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101; >70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeks Read More | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy Read More | |
JADE101 | IgA nephropathy | Phase 1 | 2026-06-01 | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101; >70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeks Read More | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in JBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
JBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
JBIOJade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences has appointed Dr. Mark Eisner to its Board of Directors, effective June 25, 2026. Dr. Eisner, with over 25 years of experience in clinical development and immunology, is expected to enhance the company's capabilities in advancing its antibody-based therapies for autoimmune diseases. His previous roles include leadership positions at Vir Biotechnology and Genentech.
Read more →JBIOJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jade Biosciences has successfully closed a public offering of 11.5 million shares, raising $172.5 million. The offering included a full exercise of the underwriters' option to purchase additional shares. The company plans to use the proceeds to fund clinical trials and research activities. Jefferies, TD Cowen, and UBS Investment Bank managed the offering.
Read more →JBIOJade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences has announced the pricing of a public offering of 10 million shares at $15.00 each, aiming to raise $150 million. The proceeds will fund clinical trials and research activities. The offering is expected to close on June 5, 2026, pending customary conditions. The company is focused on therapies for autoimmune diseases.
Read more →JBIOJade Biosciences Announces Proposed Underwritten Public Offering
Jade Biosciences, a clinical-stage biotechnology company, announced its intention to conduct an underwritten public offering of common stock and pre-funded warrants. The proceeds will support clinical trials and R&D efforts. The offering is subject to market conditions, and there is no guarantee of completion or specific terms. Jefferies, TD Cowen, and UBS are managing the offering.
Read more →JBIO▼ -11.6%on this newsshared move
Disclaimers Forward Looking Statements Certain statements contained in or made orally during this presentation, other than purely historical information, may constitute "forward-looking statements" within the meaning of
Jade Therapeutics presented interim data on its JADE101 Phase 1 study, highlighting that it has met objectives and demonstrated a favorable safety profile. The data suggests the potential for every-12-week subcutaneous dosing with significant IgA reduction. However, the company cautioned that interim results are not necessarily indicative of final outcomes and that various risks could impede future clinical trials and regulatory approvals.
Read more →JBIO▼ -11.6%on this newsshared move
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Jade Biosciences announced positive interim results from its Phase 1 trial of JADE101, an investigational treatment for IgA nephropathy. The trial showed significant IgA reductions sustained at 12 weeks, with a favorable safety profile. The company plans to advance to Phase 2 and initiate a Phase 3 trial in 2027, aiming for best-in-class status in treatment.
Read more →JBIOJade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
Jade Biosciences announced a conference call on June 1, 2026, to discuss interim results from its Phase 1 study of JADE101, a monoclonal antibody for IgA nephropathy. The results are expected to inform dosing strategies and clinical profiles. JADE101 aims to be a best-in-class treatment for this autoimmune kidney disease.
Read more →JBIOJade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Jade Biosciences has announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial for JADE101, aimed at treating immunoglobulin A nephropathy (IgAN). The trial will assess safety, tolerability, and efficacy in approximately 30 participants. Interim data is anticipated in 2027, showcasing the potential of JADE101 as a treatment option.
Read more →JBIOJade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Jade Biosciences has initiated a Phase 1 clinical trial for JADE201, a novel monoclonal antibody targeting BAFF-R to treat autoimmune diseases. The first participant has been dosed, with interim data expected in 2027. JADE201 aims to enhance B cell depletion while allowing for less frequent dosing, addressing limitations of existing therapies.
Read more →JBIOJade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences reported its Q1 2026 financial results, highlighting upcoming clinical trials for its lead candidate, JADE101, and the initiation of JADE201. The company has a robust cash position of $311 million, expected to sustain operations until mid-2028. However, it also reported a net loss of $40.4 million due to increased R&D expenses.
Read more →JBIOJade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jade Biosciences has appointed Dr. Edward R. Conner as Chief Medical Officer, granting him 500,000 stock options under the Inducement Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. Jade focuses on innovative therapies for autoimmune diseases, including its lead candidate, JADE101.
Read more →JBIO▲ +10.3%on this newsshared move
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
Jade Biosciences has appointed Dr. Edward R. Conner as Chief Medical Officer, effective immediately. Dr. Conner brings extensive experience in clinical development and regulatory strategy, which will aid in advancing the company's pipeline of therapies for autoimmune diseases. The company is preparing for key milestones, including Phase 1 data for JADE101 and a Phase 2 trial in IgA nephropathy.
Read more →JBIOJade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jade Biosciences reported its financial results for Q4 and full year 2025, highlighting a strong cash position and advancements in its clinical pipeline. The company expects to initiate several clinical trials in 2026, including JADE101 for IgA nephropathy and JADE201 for rheumatoid arthritis. Despite a rising net loss, Jade is well-positioned for future growth with a focus on best-in-class therapies for autoimmune diseases.
Read more →JBIOJade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in
Jade Biosciences, Inc. has reported its financial results for Q4 and FY 2025, highlighting strong momentum in its clinical development programs. The company has initiated its JADE101 Phase 1 study and is advancing its pipeline, including plans for the JADE201 trial to start in 2026. The focus remains on achieving key milestones, with cash reserves sufficient to support operations until 2028. However, the update also reflects financial losses and acknowledges potential risks associated with upcoming trials.
Read more →JBIOJade Biosciences to Participate in Upcoming Conferences
Jade Biosciences, a biotechnology company focused on autoimmune diseases, announced its participation in upcoming conferences where management will host investor meetings. The company's lead candidate, JADE101, is in a Phase 1 trial for immunoglobulin A nephropathy, while other candidates are in preclinical development. A live webcast of the presentations will be available on their website.
Read more →JBIO▼ -7.3%on this news
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Jade Biosciences has outlined its strategic priorities for 2026, focusing on advancing its pipeline of monoclonal antibodies for autoimmune diseases. The company anticipates key milestones for its lead candidate, JADE101, in IgA nephropathy, and plans to initiate Phase 2 trials. Jade's strong financial position is expected to support operations into 2028, positioning the company for growth.
Read more →JBIOJade Biosciences Announces $45 Million Private Placement
Jade Biosciences has announced a private placement financing agreement with BB Biotech, expected to yield approximately $45 million. The funds will be utilized for research and development, corporate expenses, and working capital. The private placement involves the sale of over 3 million shares at $14 each, set to close around December 16, 2025.
Read more →JBIO▲ +10.5%on this news· ran to +30% by day 1
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Jade Biosciences reported its Q3 2025 financial results, highlighting significant advancements in its pipeline, including the initiation of a Phase 1 study for JADE101 and the introduction of JADE201. The company presented positive preclinical data at the ASN Kidney Week, reinforcing the potential of its therapies for autoimmune diseases. Additionally, a $135 million private placement has strengthened its financial position.
Read more →JBIOJade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at th
Jade Biosciences announced its financial results for Q3 2025 and provided a corporate update, highlighting significant advancements. The company presented promising preclinical safety data for its lead candidate, JADE101, at the ASN Kidney Week, which is designed to treat IgA nephropathy. Additionally, Jade introduced a new candidate, JADE201, which is aimed at targeting autoimmune diseases, and successfully raised $135 million through private financing. The company is well-positioned to achieve multiple clinical milestones moving forward.
Read more →JBIOJade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
Jade Biosciences presented promising preclinical data for JADE101 at ASN Kidney Week 2025, highlighting its favorable safety profile and potential as a treatment for immunoglobulin A nephropathy (IgAN). The investigational drug aims to selectively inhibit APRIL, with interim data from a Phase 1 trial expected in 2026 to guide future studies. The findings suggest that biomarker responses in healthy volunteers may translate into effective outcomes for IgAN patients.
Read more →JBIO▲ +6.7%on this news
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
Jade Biosciences announced new preclinical safety and translational data for its investigational candidate, JADE101, targeting immunoglobulin A nephropathy (IgAN). The data will be presented at the American Society of Nephrology Kidney Week 2025. JADE101 aims to provide effective treatment with a patient-friendly dosing regimen. A Phase 1 trial is currently ongoing, with interim results anticipated in 2026.
Read more →JBIOJade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
Jade Biosciences has announced the development of JADE201, a novel afucosylated monoclonal antibody targeting the BAFF-R receptor, aimed at treating autoimmune diseases. This therapy is designed to offer improved efficacy and patient convenience through a dual mechanism of action and extended half-life. A first-in-human clinical trial is expected to start in early 2026, assessing safety and pharmacokinetics.
Read more →JBIOJade Biosciences Announces $135 Million Private Placement
Jade Biosciences has announced a $135 million private placement aimed at funding its research and development efforts. The financing involves the sale of common stock and pre-funded warrants, with participation from both new and existing investors. The funds are expected to support the company's operations through the first half of 2028.
Read more →JBIOJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
Jade Biosciences has announced the dosing of the first cohort in a Phase 1 clinical trial for JADE101, a monoclonal antibody targeting APRIL for IgA nephropathy. The trial aims to evaluate safety, tolerability, and pharmacokinetics. Interim data is expected in the first half of 2026, which may inform future patient studies.
Read more →JBIO▼ -7.6%on this news
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jade Biosciences reported its financial results for Q2 2025, highlighting a successful reverse merger and financing. The company is advancing its pipeline, particularly focusing on JADE101, which shows promise as a disease-modifying therapy for IgA nephropathy. Jade aims to transition into a clinical-stage company and believes it can significantly impact the treatment of autoimmune diseases.
Read more →JBIOJade Biosciences to Participate in Two Upcoming Investor Conferences
Jade Biosciences, Inc. announced its participation in two upcoming investor conferences, where CEO Tom Frohlich and CSO Andrew King will engage in discussions. The company is focused on developing therapies for autoimmune diseases, with its lead candidate, JADE101, expected to enter clinical trials in late 2025. Investor meetings will also be hosted during these events.
Read more →JBIO▲ +8.6%on this news
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Jade Biosciences has appointed Brad Dahms as Chief Financial Officer, bringing extensive experience in guiding biotech companies. Dahms previously held key financial roles at IDRx and Theseus Pharmaceuticals, contributing to significant corporate growth. Jade aims to advance its lead candidate, JADE101, for IgA nephropathy into clinical trials this year.
Read more →JBIO▲ +7.2%on this news
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
Jade Biosciences has presented preclinical data for its monoclonal antibody JADE101 at the 62nd European Renal Association Congress. The data indicates a strong binding affinity to APRIL and an extended half-life, which may facilitate infrequent dosing. Scheduled to begin first-in-human trials in late 2025, JADE101 aims to provide a disease-modifying treatment for IgA nephropathy, addressing current therapy limitations. Interim data in healthy volunteers are expected in 2026 to inform future patient studies.
Read more →JBIOJade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
Jade Biosciences announced that it will present new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress in Vienna from June 4-7, 2025. The presentation will cover the discovery and characterization of JADE101, which aims to treat IgA nephropathy, a chronic autoimmune kidney disease. The antibody is engineered for extended dosing intervals, enhancing patient convenience. A conference call will follow on June 9, 2025, to discuss the findings further.
Read more →JBIO▼ -12.3%on this news
Financial Statements. JADE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (In thousands, except share amounts)
Jade Biosciences, Inc. reported significant financial losses in its condensed consolidated balance sheet for the quarter ending March 31, 2025. The company's net loss for the period reached $38,169, leading to an increase in the accumulated deficit to $85,148. Total liabilities also increased from $119,596 to $139,832, while current liabilities grew notably in multiple categories. These results reflect the ongoing financial challenges faced by the company as it continues to develop therapies for autoimmune diseases.
Read more →JBIO▼ -12.3%on this news
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Jade Biosciences, Inc. reported its first quarter 2025 financial results and corporate updates, celebrating a successful reverse merger and debut on Nasdaq as JBIO. The company has raised approximately $300 million which will support operations through 2027. Their lead candidate, JADE101, is expected to enter clinical trials in the second half of 2025, with interim data anticipated in early 2026. However, the company reported a net loss of $38.2 million for the quarter, underscoring the financial risks it faces moving forward.
Read more →JBIOJade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
Jade Biosciences, a biotechnology company focused on therapies for autoimmune diseases, will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, in New York. CEO Tom Frohlich plans to present the company's latest developments on June 4. Additionally, Jade is expecting to initiate a first-in-human trial for its lead candidate, JADE-001, later in 2025. The company has two other antibody discovery programs in preclinical stages, indicating a robust pipeline.
Read more →JBIOCompany Overview April 2025 NASDAQ: JBIO Disclaimers Forward Looking Statements Certain statements in this presentation, other than purely historical information, may constitute forward-looking statements within the mean
Jade Biosciences outlines its forward-looking statements regarding the development of JADE-001, JADE-002, and JADE-003 in the treatment of autoimmune diseases, particularly IgA nephropathy (IgAN). The company is optimistic about JADE-001, which is projected to enter clinical trials by the second half of 2025 and could become a best-in-class treatment. With current funding extending to 2027, Jade aims to address a significant unmet need in the market, particularly among the young adult population affected by IgAN. However, the presentation emphasizes the inherent uncertainties and risks associated with the biopharmaceutical development process.
Read more →JBIOJade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
Jade Biosciences, Inc. has completed its merger with Aerovate Therapeutics, enhancing its focus on developing therapies for autoimmune diseases. The merger follows a successful private placement that raised around $300 million. Jade's lead candidate, JADE-001, is set to enter clinical trials in late 2025, targeting IgA nephropathy, a serious autoimmune condition.
Read more →JBIOJade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million Company is advancing portfolio of novel therapies that aim to redefine the
Jade Biosciences has announced the successful completion of its merger with Aerovate Therapeutics and a private placement raising approximately $300 million. The newly combined entity, operating under the name Jade Biosciences, Inc., will focus on developing innovative therapies for autoimmune diseases. With the lead candidate JADE-001 set to enter clinical trials in late 2025, the merger positions the company to advance its pipeline of treatments significantly. Additionally, the merger was coupled with a special cash dividend for pre-merger Aerovate stockholders.
Read more →JBIOAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals -Aerovate Board of Directors approves 1-for-35 reverse stock split
Aerovate Therapeutics' stockholders have approved a merger with Jade Biosciences, including all related proposals, during a special meeting. The Merger will be accompanied by a 1-for-35 reverse stock split, effectively reducing Aerovate's outstanding shares. Additionally, a cash dividend of approximately $2.40 per share will be distributed to stockholders prior to the split. Following the merger, the new entity will operate under the name Jade Biosciences, Inc., with its shares expected to trade on Nasdaq starting April 29, 2025.
Read more →JBIOAerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share Waltham, MA
Aerovate Therapeutics has declared a special cash dividend of $69.6 million, equating to approximately $2.40 per share, as part of the upcoming merger with Jade Biosciences. This dividend is contingent upon the successful closing of the merger, with stockholder approval expected at a special meeting on April 16, 2025. Notably, the cash payment will be classified as a return of capital due to Aerovate's lack of earnings and profits. The anticipated merger closing date is around April 28, 2025, subject to various conditions being met.
Read more →JBIOAerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences Cash dividend expected to be in the range of $67.6 - 69.6 million Waltham, MA
Aerovate Therapeutics has announced an expected cash dividend of $67.6 - 69.6 million in connection with its proposed merger with Jade Biosciences. This cash dividend will be paid to pre-merger Aerovate stockholders, subject to board approval. Stockholders will vote on the merger during a special meeting on April 16, 2025, with the merger expected to finalize by April 30, 2025. The announcement highlights both the potential rewards and the uncertainties associated with the merger process.
Read more →JBIOJade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit
Jade Biosciences, a biotechnology firm focused on autoimmune diseases, announced its participation in the TD Cowen's 45th Annual Health Care Conference and the Jefferies Biotech on the Beach Summit in March 2025. The management team will also be available for one-on-one investor meetings during these events, aiming to engage with potential investors. The company is working towards initiating a first-in-human trial for its lead product, JADE-001, which targets IgA nephropathy, by the second half of 2025.
Read more →JBIOJade Biosciences to Participate in Upcoming Investor Conferences
Jade Biosciences announced its participation in two investor conferences scheduled for November 2024, where CEO Tom Frohlich will present the company's developments. The events include the Stifel 2024 Healthcare Conference and the Jefferies London Healthcare Conference. This follows Jade's focus on advancing therapies for autoimmune diseases, particularly with its lead asset, JADE-001. Investors and the public can access presentations live and view archived versions for 90 days post-event.
Read more →JBIOAerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Aerovate Therapeutics and Jade Biosciences have announced a merger agreement to create a new entity focused on developing innovative therapies for autoimmune diseases. The combined company will prioritize advancing Jade's lead program, JADE-001, aimed at treating IgA nephropathy. The merger is backed by substantial financial commitments, expected to support operations through 2027. A conference call is scheduled for October 31, 2024, to discuss the merger details.
Read more →JBIOAerovate Therapeutics and Jade Biosciences Announce Merger Agreement Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients w
Aerovate Therapeutics and Jade Biosciences have announced a merger agreement aimed at advancing the development of novel therapies for autoimmune diseases, primarily through JADE-001, a monoclonal antibody targeting IgA nephropathy. This all-stock transaction, expected to close in the first half of 2025, follows Jade securing approximately $300 million from a private investment. The new company will operate under the name Jade Biosciences, with a strong financial foundation to support its pipeline. A conference call is scheduled to discuss the merger details further.
Read more →JBIOJade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million
Jade Biosciences has appointed Tom Frohlich as CEO and Hetal Kocinsky as CMO, marking a significant leadership change. The company has raised $95 million to accelerate the development of therapies for autoimmune diseases. Additionally, a new Board of Directors has been formed, comprising industry experts to guide the company's growth.
Read more →JBIOJade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases
Jade Biosciences has announced the closing of an $80 million financing round aimed at developing innovative therapies for autoimmune diseases. The funding, led by Fairmount and Venrock Healthcare Capital Partners, will support the company's mission to create targeted treatments for conditions with significant unmet medical needs. Andrew King has been appointed as Chief Scientific Officer, bringing over 15 years of relevant experience.
Read more →JBIOAerovate Therapeutics to Explore Strategic Alternatives
Aerovate Therapeutics has announced that it will explore strategic alternatives to enhance shareholder value following the cessation of its Phase 3 trial for inhaled iMatinib. The company has engaged Wedbush PacGrow as its exclusive advisor in this review process, which may result in various options including acquisitions or liquidation. No timeline has been established for the completion of this process, and Aerovate has indicated that it will not provide further updates until a decisive course of action is approved.
Read more →JBIOAerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension AV-101 did not meet the primary endpoint of change in pu
Aerovate Therapeutics reported disappointing topline results from the Phase 2b portion of the IMPAHCT trial evaluating AV-101 for pulmonary arterial hypertension. The trial did not meet its primary endpoint, showing no significant change in pulmonary vascular resistance compared to placebo, and secondary endpoints also failed to present meaningful improvements. Consequently, Aerovate will cease enrollment and discontinue the Phase 3 segment of the trial. Despite these setbacks, the drug was well tolerated among participants, and the company plans to engage with the medical community regarding the trial's implications.
Read more →JBIOAerovate Therapeutics Announces First Quarter Financial Results and Business Highlights Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmona
Aerovate Therapeutics announced its financial results for Q1 2024, highlighting key business progress. The company expects topline data from the Phase 2b portion of the IMPAHCT trial for AV-101, targeting pulmonary arterial hypertension, to be released in June 2024. Enrollment continues in the Phase 3 segment of the trial, supported by a sufficient cash runway projected to last until 2026. Despite a rise in net losses and R&D expenses, the company remains focused on delivering meaningful improvements through AV-101.
Read more →JBIOMeaningfully Improving the Lives of Patients with Rare Cardiopulmonary Disease Targeting the Hyperproliferative Cause of Pulmonary Arterial Hypertension March 2024 Nasdaq: AVTE This presentation has been prepared by Aero
Aero has reported advancements in the development of AV-101, an inhaled dry powder candidate aimed at treating pulmonary arterial hypertension (PAH). The product aims to mitigate systemic adverse events associated with oral imatinib, with critical clinical data expected from Phase 2b trials in June 2024. AV-101 is currently recognized by both FDA and EMA as an orphan drug, emphasizing its significance in addressing a substantial unmet need within the PAH patient population. While prior treatments have shown to be lacking for many patients, Aero's proactive approach positions AV-101 as a potentially impactful alternative.
Read more →JBIOAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmon
Aerovate Therapeutics reported its financial results for the full year 2023, highlighting key achievements such as the full enrollment of the Phase 2b portion of its IMPAHCT clinical trial and the first patient enrolled in the Phase 3 portion. The company expects to share topline data from the Phase 2b trial in June 2024. In addition, Aerovate expanded its intellectual property with two new patents issued in 2023. Despite these advancements, the company reported a net loss of $75.5 million for the year, influenced by rising research and development costs.
Read more →JBIOMeaningfully Improving the Lives of Patients with Rare Cardiopulmonary Disease Targeting the Hyperproliferative Cause of Pulmonary Arterial Hypertension January 2024 Nasdaq: AVTE This presentation has been prepared by Ae
Aeovate's AV-101 is a novel inhaled dry powder candidate aimed at treating pulmonary arterial hypertension (PAH), addressing significant unmet needs in the market. The drug has received orphan designations from the FDA and EMA, which supports its potential for regulatory approval. Initial clinical trials have shown that AV-101 could provide benefits similar to imatinib without the systemic adverse effects. However, challenges remain, particularly regarding the efficacy of existing treatments for PAH as indicated by the STELLAR trial outcomes.
Read more →JBIOAerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypert
Aerovate Therapeutics has completed enrollment in the Phase 2b portion and enrolled the first patient in the Phase 3 portion of the IMPAHCT trial for AV-101, a treatment for pulmonary arterial hypertension (PAH). The trial has enrolled 202 patients in Phase 2b, with topline data expected in June 2024. Furthermore, over 120 sites are actively recruiting for Phase 3, utilizing an adaptive trial design to facilitate efficient progression from Phase 2b to Phase 3. This development indicates a significant step forward for Aerovate as they aim to provide new therapeutic options for PAH patients.
Read more →JBIOAerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
Aerovate Therapeutics reported its financial results for the third quarter of 2023, highlighting progress on its IMPAHCT trial for AV-101, an inhaled formulation aimed at treating pulmonary arterial hypertension. The company is on track to report topline data from the trial in the second quarter of 2024 and has expanded its intellectual property portfolio. Despite increased research and development expenses and a higher net loss compared to the previous year, Aerovate maintains sufficient cash reserves to fund operations into 2026.
Read more →JBIOAerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
Aerovate Therapeutics has announced its financial results for the second quarter of 2023, showcasing significant advancements in its IMPAHCT clinical trial for AV-101, a treatment for pulmonary arterial hypertension. The company reported a net loss of $19 million and an increase in cash reserves to $150.1 million, which they expect will fund operations into 2026. Insights from nonclinical studies presented at the ATS 2023 conference have highlighted the promising delivery mechanism of AV-101. Aerovate's leadership also expanded with the addition of an experienced board member, bolstering their strategic direction.
Read more →JBIOAerovate Therapeutics Appoints Habib Dable To Its Board of Directors
Aerovate Therapeutics announced the appointment of Habib Dable to its Board of Directors. Dable, formerly the President and CEO of Acceleron Pharma, brings nearly 30 years of experience in the biopharmaceutical industry. His expertise is expected to support Aerovate's advancement of its novel drug AV-101 for pulmonary arterial hypertension (PAH) through clinical development. The company aims to develop significant treatment options for patients suffering from rare cardiopulmonary diseases.
Read more →JBIOAerovate Therapeutics Announces First Quarter Financial Results and Business Highlights Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 fo
Aerovate Therapeutics reported its financial results for Q1 2023 and highlighted key developments regarding its AV-101 clinical trial for pulmonary arterial hypertension. With topline Phase 2b data now projected for Q2 2024, the company has activated over 100 clinical sites across 20 countries, although patient enrollment has been slower than anticipated partly due to post-COVID factors. Financially, Aerovate is positioned to sustain operations through the second half of 2025, despite an increase in net loss and R&D expenses compared to the previous year.
Read more →JBIOAerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights Progress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Expand
Aerovate Therapeutics announced its full-year 2022 financial results, highlighting advancements in the IMPAHCT Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH). The company has expanded its intellectual property with four new patents and strengthened its management team. Financially, Aerovate reported a net loss of $51.5 million but stated it has enough funding to sustain operations into the second half of 2025. The Phase 1 AV-101 results showed promise with no serious adverse events, suggesting potential for future therapy standards in PAH treatment.
Read more →JBIOAerovate Therapeutics Appoints Donald Santel To Its Board of Directors
Aerovate Therapeutics has appointed Donald Santel to its Board of Directors, bringing over 40 years of industry experience. Santel's leadership is anticipated to greatly aid in the development of AV-101, a new treatment for pulmonary arterial hypertension (PAH). Both the CEO and Board Chair expressed confidence in Santel's capabilities to support the company's growth and innovation in addressing PAH. With a strong focus on developing drugs for rare cardiopulmonary diseases, Aerovate aims to make a significant impact on patient care through its novel therapies.
Read more →JBIOAerovate Therapeutics Announces Third Quarter 2022 Financial Results
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results WALTHAM, Mass. - November 14, 2022 - Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare
Read more →JBIOAerovate Therapeutics Announces Second Quarter 2022 Financial Results
Therapeutics Announces Second Quarter 2022 Financial Results Mass. - August 15, 2022 - Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary di
Read more →JBIOAerovate Therapeutics Announces First Quarter 2022 Financial Results
Therapeutics Announces First Quarter 2022 Financial Results Mass. - May 16, 2022 - Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseas
Read more →JBIOAerovate Therapeutics Announces Full-Year 2021 Financial Results Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021 Received FDA guidance in April 2021
Therapeutics Announces 2021 Financial Results Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021 Received FDA guidance in April 2021 that our Phase 2b/Phase 3 trial could support an NDA submission based on
Read more →JBIOAerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension
Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension Mass. - December 15, 2021 - Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully impr
Read more →JBIOAerovate Therapeutics Announces Third Quarter 2021 Financial Results
Therapeutics Announces Third Quarter 2021 Financial Results Mass. - November 15, 2021 - Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary d
Read more →JBIOAerovate Therapeutics Announces Second Quarter 2021 Financial Results
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results Mass. - August 16, 2021 - Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopu
Read more →JBIOAerovate Therapeutics Appoints Allison Dorval To Its Board of Directors Boston
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors 2021- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, t
Read more →Competitive Position
How JBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how JBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial